Literature DB >> 16918319

Thalidomide metabolism and hydrolysis: mechanisms and implications.

Erin R Lepper1, Nicola F Smith, Michael C Cox, Charity D Scripture, William D Figg.   

Abstract

Despite its controversial past, thalidomide is currently under investigation for the treatment of several disease types, ranging from inflammatory conditions to cancer. The mechanism of action of thalidomide is complex and not yet fully understood, but there is some evidence to suggest that metabolism may play a role. Consequently, there has been a considerable effort to characterize the metabolism of thalidomide in recent years. Thalidomide undergoes biotransformation by non-enzymatic hydrolysis and enzyme-mediated hydroxylation to form a multitude of metabolites. Metabolite identification and reaction phenotyping studies have been performed and will be discussed in this review in addition to interspecies differences in thalidomide metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918319     DOI: 10.2174/138920006778017777

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  20 in total

1.  Why animal studies are often poor predictors of human reactions to exposure.

Authors:  Michael B Bracken
Journal:  J R Soc Med       Date:  2009-03       Impact factor: 5.344

2.  Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

3.  Are we rushing too much?

Authors:  Michael Aschner
Journal:  Food Chem Toxicol       Date:  2020-07-05       Impact factor: 6.023

Review 4.  Current Trends of Renal Impairment in Multiple Myeloma.

Authors:  Punit Yadav; Mark Cook; Paul Cockwell
Journal:  Kidney Dis (Basel)       Date:  2016-02-03

5.  A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.

Authors:  Shandiz Shahbazi; Cody J Peer; Mark N Polizzotto; Thomas S Uldrick; Jeffrey Roth; Kathleen M Wyvill; Karen Aleman; Jerome B Zeldis; Robert Yarchoan; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2014-01-09       Impact factor: 3.935

Review 6.  Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.

Authors:  Sarah A Holstein; Philip L McCarthy
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 7.  Chemotherapy-induced peripheral neurotoxicity.

Authors:  Guido Cavaletti; Paola Marmiroli
Journal:  Nat Rev Neurol       Date:  2010-11-09       Impact factor: 42.937

Review 8.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 9.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

10.  Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.

Authors:  Christina Therapontos; Lynda Erskine; Erin R Gardner; William D Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.